Journal article
The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers
Abstract
Glioblastoma (GBM) is characterized by extensive cellular and genetic heterogeneity. Its initial presentation as primary disease (pGBM) has been subject to exhaustive molecular and cellular profiling. By contrast, our understanding of how GBM evolves to evade the selective pressure of therapy is starkly limited. The proteomic landscape of recurrent GBM (rGBM), which is refractory to most treatments used for pGBM, are poorly known. We, …
Authors
Tatari N; Khan S; Livingstone J; Zhai K; Mckenna D; Ignatchenko V; Chokshi C; Gwynne WD; Singh M; Revill S
Journal
Acta Neuropathologica, Vol. 144, No. 6, pp. 1127–1142
Publisher
Springer Nature
Publication Date
December 2022
DOI
10.1007/s00401-022-02506-4
ISSN
0001-6322